Spyre Therapeutics, Inc. financial data

Symbol
SYRE on Nasdaq
Location
Waltham, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 04 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 874 % -19.9%
Debt-to-equity 16.2 % -45.7%
Return On Equity -31.2 % +62.3%
Return On Assets -26.8 % +47.4%
Operating Margin -39.4K % -480%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 77.6M shares +50.9%
Common Stock, Shares, Outstanding 60.5M shares +17.7%
Entity Public Float 1.1B USD +4098%
Common Stock, Value, Issued 13K USD +8.33%
Weighted Average Number of Shares Outstanding, Basic 50.9M shares +1085%
Weighted Average Number of Shares Outstanding, Diluted 50.9M shares +1085%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 55.4M USD -11%
General and Administrative Expense 46.1M USD -5.97%
Operating Income (Loss) -214M USD -10.6%
Nonoperating Income (Expense) 64.7M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -149M USD +30.7%
Income Tax Expense (Benefit) -14K USD -128%
Net Income (Loss) Attributable to Parent -149M USD +30.7%
Earnings Per Share, Basic -19 USD/shares -219%
Earnings Per Share, Diluted -19 USD/shares -219%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 64.9M USD -9.34%
Cash, Cash Equivalents, and Short-term Investments 603M USD +77.7%
Assets, Current 505M USD +19.8%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 0 USD -100%
Assets 505M USD +19.8%
Accounts Payable, Current 2.85M USD +45.8%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 46.3M USD -19.6%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 49.5M USD -47.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 791K USD -45.7%
Retained Earnings (Accumulated Deficit) -1.07B USD -16.3%
Stockholders' Equity Attributable to Parent 455M USD +39%
Liabilities and Equity 505M USD +19.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -41M USD -43.6%
Net Cash Provided by (Used in) Financing Activities 125K USD -99.9%
Net Cash Provided by (Used in) Investing Activities -61K USD +99.9%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 60.5M shares +17.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -40.9M USD -206%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 64.9M USD -9.34%
Deferred Tax Assets, Valuation Allowance 163M USD +29.8%
Deferred Tax Assets, Gross 163M USD +29.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -150M USD +29.9%
Property, Plant and Equipment, Gross 0 USD -100%
Operating Lease, Liability, Current 0 USD -100%
Operating Lease, Weighted Average Discount Rate, Percent 0 pure -104%
Deferred Tax Assets, Operating Loss Carryforwards 87.3M USD +17.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares +14.1%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 0 USD -100%
Share-based Payment Arrangement, Expense 9.57M USD -27%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%